Effects of Long-acting Injectable 3-Monthly Paliperidone Palmitate on the Clinical and Social Performance of Patients with Schizophrenia
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Oh, Jihoon | - |
dc.contributor.author | Oh, Jihye | - |
dc.contributor.author | Kim, Dong Wook | - |
dc.contributor.author | Youn, HyunChul | - |
dc.contributor.author | Kim, Sae-Hoon | - |
dc.contributor.author | Kim, Soo In | - |
dc.contributor.author | Chung, In Won | - |
dc.contributor.author | Wang, Kuan Shu | - |
dc.contributor.author | Kim, Minah | - |
dc.contributor.author | Paik, Jong -Woo | - |
dc.contributor.author | Koh, Min Jung | - |
dc.contributor.author | Lee, Yoosun | - |
dc.contributor.author | Choi, Seok Young | - |
dc.contributor.author | Kim, Jung-Jin | - |
dc.date.accessioned | 2023-05-25T01:41:36Z | - |
dc.date.available | 2023-05-25T01:41:36Z | - |
dc.date.issued | 2023-02 | - |
dc.identifier.issn | 1738-1088 | - |
dc.identifier.issn | 2093-4327 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/22452 | - |
dc.description.abstract | Objective: To investigate the effects of long-acting injectable 3-monthly paliperidone palmitate on the clinical and social functioning of patients with schizophrenia. Methods: This study enrolled patients with schizophrenia receiving long-acting injectable 1-monthly paliperidone palmi-tate for at least 4 months and who subsequently received 3-monthly paliperidone palmitate. Accordingly, 418 patients were followed up for 24 weeks. Their clinical symptoms and social functioning were measured using the Clinical Global Impression-Severity of Illness and Personal and Social Performance scales. Results: The Personal and Social Performance total score was significantly higher after 3-monthly paliperidone palmitate treatment than at baseline (baseline vs. week 24: 54.3 +/- 18.0 vs. 61.0 +/- 14.5 [mean +/- standard deviation]; p < 0.001; Wilcoxon signed-rank test); the proportion of patients in the mildly ill group (scores 71-100) also increased significantly (baseline vs. week 24: 16.5% vs. 20.6%; p < 0.001; McNemar-Bowker test). The mean Clinical Global Impression-Severity of Illness score decreased significantly (baseline vs. week 24: 3.7 +/- 1.0 vs. 3.4 +/- 0.9; p < 0.001; Wilcoxon signed-rank test), as did the proportion of patients in the severely ill group (baseline vs. week 24: 4.1% vs. 2.1%; p < 0.001; McNemar-Bowker test). Conclusion: Continuous 3-monthly paliperidone palmitate treatment significantly enhances the personal and social per-formance of patients with schizophrenia and reduces the proportion of those with severe illness. These findings suggest that long-acting injectable antipsychotic administration at intervals longer than 1 month might improve the social func-tioning of and promote return to activities of daily living in patients with schizophrenia. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한정신약물학회 | - |
dc.title | Effects of Long-acting Injectable 3-Monthly Paliperidone Palmitate on the Clinical and Social Performance of Patients with Schizophrenia | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.9758/cpn.2023.21.1.126 | - |
dc.identifier.wosid | 000928396500010 | - |
dc.identifier.bibliographicCitation | Clinical Psychopharmacology and Neuroscience, v.21, no.2, pp 126 - 134 | - |
dc.citation.title | Clinical Psychopharmacology and Neuroscience | - |
dc.citation.volume | 21 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 126 | - |
dc.citation.endPage | 134 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Neurosciences | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | ANTIPSYCHOTICS | - |
dc.subject.keywordPlus | SCALE | - |
dc.subject.keywordAuthor | KEY WORDS | - |
dc.subject.keywordAuthor | Schizophrenia | - |
dc.subject.keywordAuthor | Antipsychotics | - |
dc.subject.keywordAuthor | Paliperidone palmitate | - |
dc.subject.keywordAuthor | Clinical global impression | - |
dc.subject.keywordAuthor | Personal and social performance | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.